Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Dynacure secures $55M as their Ionis-developed drug moves into clinic

6 years ago

FDA puts pediatric aGVHD drug on priority review lane — will they go virtual with the adcomm?

6 years ago

Daiichi Sankyo sinks $200M into new gene therapy tech from Ultragenyx

6 years ago

Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb

6 years ago

VBL and its 'gene therapy' cancer treatment are back — with a peek at PhIII potential

6 years ago

Turn on, tune in: New York biotech scores $15M+ in chemogenetics bet

6 years ago

How to build CAR–M: Carl June protégé and his biotech publish first evidence in Nature Biotechnology

6 years ago

To arm the immune system for sustained attack against HIV, NIH scientists take to viral vectors

6 years ago

J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO

6 years ago

Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

6 years ago

Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital

6 years ago

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

6 years ago

Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round

6 years ago

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

6 years ago

Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused Sangamo

6 years ago

Spark loses another top exec in the wake of $4.3B takeover by Roche — report

6 years ago

'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms

6 years ago

Will a 'risk-off' mindset hasten cell therapy M&A? Iovance surges on buyout chatter

6 years ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

6 years ago

Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy

6 years ago

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

6 years ago

TCR-focused Immatics adds another marquee name to its list of partners: GSK

6 years ago

FDA slaps a hold on LogicBio and its gene editing plans — shares tumble

6 years ago

From mice to dogs, and someday man: George Church's gene therapy cocktail for aging-related diseases

6 years ago

First page Previous page 47 48 495051 52 53 Next page Last page